Last reviewed · How we verify
NCT05696379
Angiography Derived Index of Microcirculatory Resistance in Patients With Acute Myocardial Infarction
trial testing Angiography derived index of micro-circulatory resistance (Angio-IMR) in Acute Myocardial Infarction (AMI) in 5,000 participants. Completed in 31 May 2022.
31 May 2022
Quick facts
| Lead sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 5,000 |
| Start date | 1 June 2017 |
| Primary completion | 31 May 2022 |
| Estimated completion | 31 May 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- Angiography derived index of micro-circulatory resistance (Angio-IMR)
Conditions studied
- Acute Myocardial Infarction (AMI) — all drugs for Acute Myocardial Infarction (AMI) →
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Who can join
18 and older, any sex, with Acute Myocardial Infarction (AMI). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Coronary microcirculatory dysfunction has been known to be prevalent even after successful revascularization of acute myocardial infarction (AMI) patients, and has been shown to be associated with poor prognosis. Angiography derived index of micro-circulatory resistance (Angio-IMR) is a novel pressure-wire free approach to assess coronary microvascular disease with great diagnostic performance. The current study will further investigate the prognostic value of Angio-IMR in patients with AMI in multicenter retrospective cohort.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Prognostic Value of Coronary Angiography-Derived Index of Microcirculatory Resistance in Non-ST-Segment Elevation Myocardial Infarction Patients.
Zhang Y, Pu J, Niu T, Fang J, et al · · 2024 · cited 19× · PMID 39115479 · DOI 10.1016/j.jcin.2024.04.048 -
Combined risk estimates of diabetes and coronary angiography-derived index of microcirculatory resistance in patients with non-ST elevation myocardial infarction.
Chen D, Zhang Y, Yidilisi A, Hu D, et al · · 2024 · cited 5× · PMID 39152477 · DOI 10.1186/s12933-024-02400-1 -
Thorough Physiological Assessment in Non-Culprit Vessels of Patients with Acute Myocardial Infarction: Is It a Required Action?
Chen Z, Zhang Y, Fang J, Zheng Y, et al · · 2026 · cited 1× · PMID 40913743 · DOI 10.1007/s10557-025-07768-0
Verify or expand the search:
- PubMed search for NCT05696379
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Myocardial Infarction (AMI)
Currently open trials in the same condition.
- NCT07400601 — A Clinical Cohort Registry Study on Primary PCI for Acute Myocardial Infarction at Zhongshan Hospital · recruiting
- NCT07208006 — Very Early PCSK9 Inhibition for Acute Myocardial Infarction · NA · recruiting
- NCT07537296 — Coronary and Myocardial Evaluation by Cardiac CT for Acute Myocardial Infarction · recruiting
- NCT07276282 — Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction · Phase 3 · recruiting
- NCT07293923 — Magenta Elevate™ Clinical Feasibility Study in Cardiogenic Shock · NA · recruiting
Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials
Trials by the same sponsor.
- NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
- NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
- NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
- NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
- NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05696379 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
- Last refreshed: 25 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05696379.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing